Across TCGA pan-cancer cohorts, PRKX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRKX data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PRKX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKX expression acts as an unfavorable survival marker.

SKCM, UCEC, and HNSC are the cancer types where PRKX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.036	0.728	<.001	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	IV	0.148	0.669	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRKX tumor-vs-normal RNA expression · all PRKX data types